

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**M. 10503 - SK CAPITAL / SEQENS**

**SECTION 1.2**

**Description of the concentration**

On 5 November 2021, the European Commission received notification of a proposed concentration pursuant to which SK Grand Prix Holdings LP, an entity which is ultimately controlled by funds advised and/or managed by SK Capital Partners, LP (“**SKCP**”), will acquire sole control over Seqens Group Holding SAS and its subsidiaries (together, “**Seqens**”), through special purpose vehicles, within the meaning of Article 3(1)(b) of the EU Merger Regulation. The proposed transaction relates to the purchase of all the issued interests in the share capital of Seqens by SKCP.

The business activities of the Parties are as follows:

- SKCP is a US-based private investment firm focused on the specialty materials, chemicals and pharmaceutical sectors.
  
- Seqens is a French company active in the business of the international manufacturing and distribution of diversified essential chemicals, pharmaceutical solutions and specialty ingredients that are used in everyday products.